Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37Belgium
+32 (0)32 86 69 80Switzerland
+41 (0)43 377 11 11We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00United States of America
+1 (0)21 237 601 34Financial Adviser
Van Lanschot Kempen acted as Financial Adviser to NewAmsterdam Pharma in the USD 182 million secondary sell-down by existing shareholders
NewAmsterdam Pharma (Nasdaq: NAMS) is a clinical-stage biotechnology company focused on improving patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or tolerated. Its lead candidate, obicetrapib, is an oral, low-dose and once-daily CETP inhibitor, as the currently preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients.
NewAmsterdam Pharma recently completed a business combination with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, after which it became a Nasdaq-listed company. NewAmsterdam Pharma is based in the Netherlands.
In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: